The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 28, 2025

Filed:

Oct. 15, 2021
Applicants:

The Uab Research Foundation, Birmingham, AL (US);

Southern Research Institute, Birmingham, AL (US);

Inventors:

William B. Parker, Birmingham, AL (US);

Eric J. Sorscher, Birmingham, AL (US);

Assignees:

The UAB Research Foundation, Birmingham, AL (US);

Southern Research Institute, Birmingham, AL (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/47 (2006.01); A61K 9/06 (2006.01); A61K 9/16 (2006.01); A61K 31/7076 (2006.01); A61K 38/45 (2006.01); A61K 38/46 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
A61K 38/47 (2013.01); A61K 9/06 (2013.01); A61K 9/1641 (2013.01); A61K 9/1647 (2013.01); A61K 31/7076 (2013.01); A61K 38/45 (2013.01); A61K 38/465 (2013.01); A61K 48/00 (2013.01); Y02A 50/30 (2018.01);
Abstract

The use of a purine nucleoside phosphorylase or nucleoside hydrolase or a vector encoding expression of one of these enzymes is detailed along with the use of a prodrug cleaved by the purine nucleoside phosphorylase or nucleoside hydrolase for the preparation of a direct injection inhibition of replicating or non-replicating targeted cells. The targeted cells do not normally express the introduced purine nucleoside phosphorylase or nucleoside hydrolase. The enzyme and prodrug are amenable to intermixing and injection as a single dose or as separate injection or administration to the targeted cells. The substance and prodrug efficacy are enhanced through exposure of the targeted cells to X-ray radiation. Administration of a prodrug regardless of administration route to the targeted cells is effective in combination with X-ray radiation therapy to kill or inhibit function of the targeted cells.


Find Patent Forward Citations

Loading…